Replies to post #84950 on Biotech Values

[alertmeipp]

they strike a deal with NVS. 200M upfront.

[turtlepower]

VNDA - Wow. I agreed with most of the posters that thought this was way overvalued. Guess I was wrong.

[DewDiligence]

The VNDA deal completes a “full circle” maneuver for NVS, who owned the worldwide rights to this drug a few years ago but decided, after running QT-prolongation studies, that it had no commercial potential.

One could say that NVS screwed up, or one could say they are showing wisdom and maturity by being unconcerned about losing face.